Abstract
Omicron, the novel highly mutated SARS-CoV-2 Variant of Concern (VOC, Pango lineage B.1.1.529), was first collected in early November 2021 in South Africa. By the end of November 2021, it had spread and approached fixation in South Africa, and had been detected on all continents. We analyzed the exponential growth of Omicron over the four-week periods in two most populated South Africa’s provinces, Gauteng and KwaZulu-Natal, arriving at the doubling time estimates of respectively 3.3 days [95% CI: 3.2–3.4 days] and 2.7 days [95% CI: 2.3–3.3 days]. Similar or even shorter doubling times were observed in other locations: Australia (3.0 days), New York State (2.5 days), UK (2.4 days), and Denmark (2.0 days). Log– linear regression suggests that the spread began in Gauteng around October 11, 2021, however, due to presumable stochasticity in the initial spread, this estimate can be inaccurate. Phylogenetics-based analysis indicates that the Omicron strain started to diverge in between October 6 and October 29, 2021. We estimated that the weekly growth of the ratio of Omicron to Delta is in the range 7.2–10.2, considerably higher than the growth of the ratio of Delta to Alpha (estimated to be in in the range 2.5–4.2), and Alpha to pre-existing strains (estimated to be in the range of 1.8–2.7). High relative growth does not necessarily imply higher Omicron infectivity. A two-strain SEIR model suggests that the growth advantage of Omicron may stem from immune evasion, which permits this VOC to infect both the recovered and the fully vaccinated individuals. As we demonstrated within the model, immune evasion is more concerning than increased transmissibility, because it can facilitate larger epidemic outbreaks.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the National Science Centre Poland OPUS grant 2018/29/B/NZ2/00668 and Norwegian Financial Mechanism GRIEG-1 grant 2019/34/H/NZ6/00699 (operated by the National Science Centre Poland). The funding agencies had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
We support our findings, originally employing data from the Gauteng province of South Africa, using additional data documenting the Omicron outbreak in other locations: the second most populated South Africa's province, KwaZulu-Natal, and the UK, Denmark, New York State, and Australia (see Fig. 2 and Fig. 3). Additional data used in revision were unavailable at the time of the original submission. To clarify the issue of breaking herd immunity we constructed a two-strain mathematical model, with the help of which we analyzed consequences of higher transmissibility of Omicron versus its ability to infect a pool of individuals resistant to Delta variant (see Fig. 4). To appropriately reflect the extended analysis in the revised manuscript we modified the manuscript title.
Data Availability
We analyzed publicly available genome datasets retrieved from GISAID (https://www.gisaid.org) and Community Mobility Reports available from Google (https://www.google.com/covid19/mobility/). Cases data for Gauteng and KwaZulu-Natal can be found in daily reports from the National Institute for Communicable Diseases (https://www.nicd.ac.za) as aggregated by the University of Pretoria (https://github.com/dsfsi/covid19za). Cases for all other regions can be found in data aggregated by Johns Hopkins University (https://github.com/CSSEGISandData/COVID-19). Mutation counts for Omicron sequences can be found on Nextstrain (https://nextstrain.org/groups/neherlab/ncov/21Kdiversity).
https://www.google.com/covid19/mobility/
https://github.com/dsfsi/covid19za
